Background Circle Background Circle

NIH Halts Trial of Convalescent Plasma for Mild COVID-19

NIH Halts Trial of Convalescent Plasma for Mild COVID-19

By Robert Preidt

HealthDay Reporter

WEDNESDAY, March 3, 2021 (HealthDay News) — A clinical trial evaluating the use of convalescent plasma in patients with mild to moderate COVID-19 symptoms has been halted because the treatment didn’t benefit them, according to the U.S. National Institutes of Health.

Convalescent plasma (also called “survivor’s plasma”) is derived from the blood of patients who have already recovered from COVID-19. It’s thought that infusions of the antibody-rich plasma might give patients an extra weapon to fight off SARS-CoV-2.

The NIH study included patients seen at an emergency department who’s had mild to moderate coronavirus symptoms for a week or less.

However, “even if enrollment continued, this trial was highly unlikely to demonstrate that COVID-19 convalescent plasma prevents progression from mild to severe illness” in at-risk patients who seek emergency care but are not hospitalized, an NIH news release said.

The trial to assess the safety and effectiveness of the therapy began in August and included 47 emergency departments nationwide. Of the 900 adult patients it sought to recruit, 511 were enrolled before the trial was halted. Patients had at least one risk factor associated with severe COVID, such as obesity, high blood pressure, diabetes, heart disease or chronic lung disease. But when they arrived at the ER, none were sick enough to be hospitalized.

Study participants received either convalescent plasma or a placebo. They were then followed to assess three outcomes: If they sought further emergency or urgent care, if they had to be hospitalized, or if they died within 15 days of entering the trial.

While the study found the treatment to be safe, the researchers found no significant differences in the three outcomes between those who received the COVID-19 convalescent plasma or the placebo.

An independent monitoring board recommended halting the trial after a Feb. 25 meeting, and the study stopped enrolling new patients.

Based on earlier studies that suggested convalescent plasma might be of benefit, more than 100,000 people in the United States and many more worldwide have been given the therapy since the pandemic began.


Continued

The findings contrast with a small Argentinian study of 160 elderly patients who were infected but not yet sick enough to be hospitalized. That study, published in January in the New England Journal of Medicine, concluded that convalescent plasma could help prevent severe illness in older patients who were newly infected with coronavirus.

Researchers in that study said two factors were key: Donor plasma had to be given within 72 hours of the start of symptoms, and the plasma must have a high concentration of antibodies.


More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19.


SOURCE: U.S. National Institutes of Health, news release, March 2, 2021



WebMD News from HealthDay



Copyright © 2013-2020 HealthDay. All rights reserved.

Source link

You Might Also Like!
Southern California Is Origin of New COVID-19 Variant
Southern California Is Origin of New COVID-19 Variant

FRIDAY, Feb. 12, 2021 (HealthDay News) -- A new variant of COVID-19 found in Southern California is coursing across the ENGAGE+

COVID-19 vaccines: Safety, side effects — and coincidence
COVID-19 vaccines: Safety, side effects — and coincidence

As the pandemic rages on, it’s increasingly clear that widespread vaccination is essential to help contain it. Physical distancing, universal ENGAGE+

Give Hospitalized COVID-19 Patients Blood Thinners
Give Hospitalized COVID-19 Patients Blood Thinners

By Robert Preidt HealthDay Reporter FRIDAY, Feb. 12, 2021 (HealthDay News) -- Giving blood thinners to COVID-19 patients soon after ENGAGE+

Covid-19: Vaccine as good in 'real world' as in trial in Israel
Covid-19: Vaccine as good in 'real world' as in trial in Israel

The Pfizer vaccine prevented 94% of infections in a group of 600,000 Israeli patients. Source link

Walmart, Walgreens, CVS to Offer COVID-19 Vaccines
Walmart, Walgreens, CVS to Offer COVID-19 Vaccines

Feb. 11, 2021 -- Walmart, Sam’s Club, and Walgreens will begin offering COVID-19 vaccines on Friday through the Federal Retail ENGAGE+

Experts Debunk COVID-19 Vaccine-Shingles Link
Experts Debunk COVID-19 Vaccine-Shingles Link

Feb. 9, 2021 -- The Reddit message board user was looking for others in similar misery to share their stories. ENGAGE+

Beyond COVID-19: Can mRNA Treat Diseases, Too?
Beyond COVID-19: Can mRNA Treat Diseases, Too?

Secondly, the FDA has yet to greenlight any of these treatments. What’s more, some early trials of mRNA therapies have ENGAGE+

Add Gum Disease to List of Risk Factors for Severe COVID-19
Add Gum Disease to List of Risk Factors for Severe COVID-19

TUESDAY, Feb. 9, 2021 (HealthDay News) -- Keep flossing: A new study finds that gum disease may raise the chances ENGAGE+